SC&H Financial Advisors Inc. Sells 5,606 Shares of BioAtla, Inc. (NASDAQ:BCAB)

SC&H Financial Advisors Inc. reduced its stake in shares of BioAtla, Inc. (NASDAQ:BCAB) by 7.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,519 shares of the company’s stock after selling 5,606 shares during the quarter. SC&H Financial Advisors Inc.’s holdings in BioAtla were worth $161,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Vontobel Holding Ltd. lifted its stake in BioAtla by 26.4% in the 3rd quarter. Vontobel Holding Ltd. now owns 715,195 shares of the company’s stock valued at $1,216,000 after acquiring an additional 149,544 shares in the last quarter. Sectoral Asset Management Inc. raised its stake in shares of BioAtla by 26.9% during the 3rd quarter. Sectoral Asset Management Inc. now owns 706,062 shares of the company’s stock worth $1,200,000 after purchasing an additional 149,544 shares in the last quarter. Formidable Asset Management LLC raised its stake in shares of BioAtla by 79.0% during the 3rd quarter. Formidable Asset Management LLC now owns 162,794 shares of the company’s stock worth $277,000 after purchasing an additional 71,859 shares in the last quarter. Panagora Asset Management Inc. acquired a new position in shares of BioAtla during the 3rd quarter worth approximately $90,000. Finally, SG Americas Securities LLC acquired a new position in shares of BioAtla during the 3rd quarter worth approximately $37,000. 77.23% of the stock is currently owned by institutional investors and hedge funds.

BioAtla Trading Up 3.2 %

NASDAQ BCAB traded up $0.07 during trading hours on Tuesday, hitting $2.25. 245,566 shares of the company’s stock were exchanged, compared to its average volume of 506,003. BioAtla, Inc. has a 1-year low of $1.24 and a 1-year high of $4.07. The stock has a 50-day simple moving average of $2.80 and a 200 day simple moving average of $2.25.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.12. Research analysts expect that BioAtla, Inc. will post -1.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on BCAB. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 price objective on shares of BioAtla in a report on Thursday, March 28th. HC Wainwright dropped their price objective on BioAtla from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, March 27th.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.